Ivonescimab with Chemotherapy Shows Significant Overall Survival Benefit in Squamous NSCLC

Akeso announced that its drug Ivonescimab, when combined with chemotherapy, demonstrated a statistically significant overall survival benefit in the first-line treatment of patients with squamous non-small cell lung cancer (NSCLC) in the HARMONi-6 study conducted in China. This represents a notable development in oncology, offering a new potential treatment option for patients with this aggressive form of lung cancer. The evidence level is based on clinical trial results.